Business Wire

TELEROUTE

17.9.2020 10:02:04 CEST | Business Wire | Press release

Share
Teleroute, Part of Alpega Group, Confirms Robust Recovery of Freight Offers After Coronavirus Shock

The activity registered on the Teleroute Freight Exchange has been experiencing an upward trend for several weeks following the strong increase in demand for their solution during the Coronavirus crisis, demonstrating the resilience and anti-cyclical nature of one of Europe’s leading freight exchanges.

After the initial shock to the European market due to the Coronavirus, the Teleroute Freight Exchange, that together with 123Cargo and Wtransnet form one of the largest European transport collaboration networks, confirms the return of activity with a notable upturn in the number of freight offers in recent weeks , placing the activity at pre-coronavirus level and even higher in the last weeks of July, exhibiting none of the typical seasonal slowdown.

The most difficult moment for the transportation industry due to the crisis took place in April, where the complete stoppage of industrial activity throughout Europe caused freight volume to drop dramatically. This period was then followed by a second disrupted supply chain period where freight forwarders and carriers, looking for new routes for new volumes, turned to Teleroute to manage demand and the number of new users on Teleroute grew by 1,200.

Speaking about this trend, Fabrice Douteaud, COO of Teleroute, said: “We are very proud of the resilience shown by the transport & freight forwarding companies by continuing their important work during these very difficult times. We have experienced an exceptional demand for our freight exchange during this crisis, a proof of the value we bring to the market: facilitating the collaboration of transport professionals.”

France, the driving force behind the recovery of freight offers in Europe

After the month of April with volume below average, we are in the middle of the summer with a very notable recovery of the freight offers on Teleroute with France as the country of origin, which has doubled.

This leaves us with an activity in July that has far exceeded the monthly average number of published freight offers, mainly in the domestic market (90% of volumes) and in exports to Belgium, Germany and Spain in equal parts.

On the other hand, if we look at imports, the numbers are even better, in the last two months we find volumes well above the usual and that shows the recovery of the main countries that send merchandise to France: Italy, which leads the ranking with 37% of freight offers; Germany (29%), Belgium (23%) and Spain (7%).

Italy doubles its transport activity in July thanks to exports

Regarding the data obtained from the freight offers published on Teleroute originating in Italy, one of the countries most affected by the pandemic, we find a surprising recovery in July where the volume has doubled thanks to the reactivation of transactions with France, which account for 57% of Italian exports. Germany with 18% and Spain with 15% close the top 3.

In relation to inbound freight, the transalpine country doubled the number of import offers in July compared to previous months, placing activity above the average in 2019 and only slightly lower than the months with the highest activity on the freight exchange. A comeback led by the flow of goods with France, with 40% of the freight offers published, and Germany (15%) as the main countries offering freight to the Italian market.

Huge growth in the German domestic transport market

Focusing on Germany , another of the European economy's main drivers, we observed a strong rebound in activity in July with 25% above the monthly average in 2019, the domestic market's upward growth, which was already palpable in June, and accounting for 50% of the freight offers with Germany as origin and/or destination.

The other freight offers, are divided into 28% imports, mainly from Italy and France, and exports (remaining 22%) whose main destinations are France and the Netherlands.

Numbers that, in accordance with the offers registered in Teleroute, place the European transport market that Teleroute serves, already back to normal in practically the entire region and, on the current trajectory, will be performing ahead of 2019 for the remainder of the year.

Alpega Group

End-to-End Transportation software

Alpega Group is a leading global logistics software company offering modular solutions that cover all transportation and logistics complexity needs. By bringing together the best solutions and market expertise, the Alpega Group has created the transportation industry’s only scalable end-to-end software suite.

Alpega TMS empowers transport professionals to manage the logistics and supply chain processes, it transforms global and local supply chains into collaborative ecosystems, bringing together all parties involved. Alpega TMS’s unique scalability and best-in-breed standalone solutions ensure shippers benefit from a system that evolves alongside their needs, regardless of the complexity of their logistics processes. Our freight procurement solution, TenderEasy, provides a world-class solution for sourcing transportation providers across air, land and sea. In terms of freight exchanges, 123Cargo, Teleroute and Wtransnet are leading European marketplaces designed to match spot shipments and truck capacity.

These platforms and the data which flows through them, alongside our 30+ years’ experience in transportation lets us enable businesses to optimize their supply chain planning and execution while benefitting from lower costs and higher visibility. All of Alpega’s solutions combine to create added value for customers. Our community of 80,000 carriers and 200,000 members are electronically connected every day to successfully manage critical transport processes. Alpega is present in 80 countries worldwide and employs 500 people with 31 different nationalities.

More information can be found at www.alpegagroup.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye